Forget Antibodies. Use Aptamers!™ Forget Antibodies. Use Aptamers!™

R&D Support

Complete this 4-step form to receive a PDF Quote on your project Cost & Time.

  • 1

    Step 1 Target Type

  • 2

    Step 2 Target Details

  • 3

    Step 3 Cost Time

  • 4

    Step 4 Contact Info

Intellectual Property (IP):
Aptagen owns the proprietary process of aptamer development; however, the Client will own 100% of the rights to the aptamers Aptagen develops for the Client. Client contracts Aptagen to perform the R&D, the Client owns the IP.

PRICE MATCH GUARANTEE: Contact Us. We will make every effort to match any competitor’s quote (for equivalent services).  Just provide documentation.  Thank you.

Depending on Client needs, the project may be tailored to meet certain milestone objectives such as:

  • High Affinity (Kd) AND High Specificity; eliminate (false-positive) cross-reactivity.
  • Wide dynamic range between positive and negative samples (LOD)
  • Activation (EC50) or inhibition (IC50) against a target enzyme
  • Identification of unknown and unique biomarkers in serum, blood, or tissue samples
  • Cell or tissue-targeting for drug delivery
  • Convert an already existing aptamer into an apta-beacon™ to detect analytes free in solution (see Apta-Beacons™)

The target sample(s) do not have to be pure; crude target sample(s) are acceptable.

Phase I: Screening/Selection

Description

Iterative rounds of screening an initial random library against a target for positive selection, and counter-selection against a counter-target for specificity. 

Client Materials: Please note that the Client will need to provide the target(s) for Aptagen. It is highly recommended that countertarget(s) is also provided for enrichment of highly specific apta-sensors. A Material Acquisition Form must be completed for background information on the target, any associated hazards, and handling requirements.

Target Type

Small Targets: Small Molecules or Peptides

Large Targets: Proteins, Biomarkers, Cells, Tissues

Deliverable: The most promising monoclonal apta-sensor candidates are identified using proprietary bioinformatics. A full Progress/Analysis Report on a handful of the most likely candidates based on sequence homology, frequency, and motif analysis.

Proteins or high MW Biomarkers
« 2 of 5 »

Phase II: Sequencing and Bioinformatics

Description

The enriched polyclonal pool is sequenced and thousands of apta-sensor sequences are provided. Client will have access to all the data generated from the polyclonal apta-sensor pool in Phase I (hundreds to thousands of sequences).

Deliverable

Deliverable: The most promising monoclonal apta-sensor candidates are identified using proprietary bioinformatics. A full Progress/Analysis Report on a handful of the most likely candidates based on sequence homology, frequency, and motif analysis.

Phase III: Synthesis of Candidates

Description

Monoclonal apta-sensor oligo candidate(s) are synthesized, purified, and QC. Projects are typically based on unmodified apta-sensors. 

Note: This Phase is at the Client’s discretion whether Aptagen performs the work or is performed by another provider.

Deliverable

Deliverable: 1 nmole of purified apta-sensors for Phase IV

Phase IV: Validation (Characterization) of Candidates

Description

Each tested for assessing Kd affinities, signal-to-background, LOD, targeting, or EC50/IC50, etc..  

Note: This Phase is at the Client’s discretion whether Aptagen performs the work or is performed by another provider.

Assay Type

ForteBio, Thermophoresis, Dot Blot, Gel-shift assay, or ELONA (ELISA), Microscopy, Flow Cytometry, or Imaging, etc

Deliverable: Full Report on Kd Affinities and Specificities. 

Phase V: Optimization (optional)

Description

At the Client’s discretion, Aptagen may ‘multimerize’ apta-sensors to further enhance functional properties of apta-sensor candidate(s) while truncating or minimizing the length of the oligo to reduce large-scale manufacturing costs and processing time downstream. Aptagen’s proprietary in silico algorithm searches and explores ‘sequence space.’  Inquire. Project specific. The Optimization Phase may not be necessary for research purposes. This phase entails truncation of apta-sensor oligos to reduce production costs for commercialization or ‘multimerization’ of apta-sensors to further increase affinity/avidity. This Phase may trigger only if Client believes Optimization a) is cost effective to minimize production costs while maximizing activity for large-scale commercial use and/or, b) widens the claims in Client’s IP to strengthen the coverage of all possible apta-sensor sequence variants.

Thank you for contacting Aptagen regarding your aptamer development needs. We can develop aptamers against your target(s) of interest.


Complete this 4-step form to receive a PDF Quote on your project Cost & Time.

Note: We do not synthesize aptamer oligos. We only specialize in developing/discovering new aptamer sequences that can be easily synthesized by any “oligo house” supplier.  Refer to our Affiliates page for oligo synthesis work.

Aptagen, LLC | 250 North Main Street | Jacobus, PA 17407

Forget Antibodies. Use Aptamers!™ Forget Antibodies. Use Aptamers!™